Virologic (NASDAQ:VLGC)
Historical Stock Chart
From Aug 2019 to Aug 2024
ViroLogic to Host Panel on Personalized Medicine at BIO 2004
SOUTH SAN FRANCISCO, Calif., June 3 /PRNewswire-FirstCall/ -- ViroLogic, Inc.
(NASDAQ:VLGC) today announced that Bill Young, Chairman and CEO, will moderate
a panel entitled "Making Personalized Medicine a Reality" at BIO 2004 on
Tuesday, June 8, 2004, 4:00 - 5:30 p.m. EDT in Room 2005 West Building, 747
Howard Street in San Francisco.
The panel will also feature executives from other leading biotechnology
companies focused on personalized medicine for cancer, infectious and other
serious diseases. The panel includes:
-- Gordon Ringold, Co-founder, Chairman & CEO, SurroMed, Inc.
-- Steven Shak, M.D., Chief Medical Officer, Genomic Health, Inc.
-- Sharat Singh, Ph.D., Chief Technical Officer, ACLARA Biosciences, Inc.
-- Jeannette Whitcomb, Ph.D., Vice President, Operations, ViroLogic, Inc.
-- Emily Winn-Deen, Senior Director, Genomics Business, Roche Molecular
Diagnostics
"Tailoring therapy to the individual genetic make-up of the patient or the
disease-causing agent maximizes the likelihood that treatment will be not only
successful, but also potentially more cost-effective," said Young. "Informed
and judicious use of drugs can save the health-care system millions of dollars
each year. However, the promise of personalized medicine is dependent on the
use of diagnostic and disease-monitoring technologies to match the right
patient with the right drug."
This panel will explore current examples of these technologies and what the
industry expects to see in the near future. Interviews and one-on-one briefings
with panel participants are available upon request by contacting Carolyn
Bumgardner Wang at 415-362-5018 or .
About ViroLogic
ViroLogic (the "Company") is a biotechnology company advancing individualized
medicine by discovering, developing and marketing innovative products to guide
and improve treatment of serious infectious diseases such as AIDS and
hepatitis. The Company's products are designed to help doctors optimize
treatment regimens for their patients that lead to better outcomes and reduced
costs. The Company's technology is also being used by numerous
biopharmaceutical companies to develop new and improved antiviral therapeutics
and vaccines targeted at emerging drug-resistant viruses. More information
about the Company and its technology can be found on its web site at
http://www.virologic.com/ .
Certain statements in this press release are forward-looking, including
statements relating to personalized medicine. These forward-looking statements
are subject to risks and uncertainties and other factors, which may cause
actual results to differ materially from the anticipated results or other
expectations expressed in such forward-looking statements. These risks and
uncertainties include, but are not limited to, the risks that the Company's
products may not perform in the same manner as indicated in this press release,
whether ViroLogic successfully introduces new products, whether others
introduce competitive products, the risk that the Company's products for
patient testing may not continue to be accepted or that increased demand from
drug development partners may not develop as anticipated, the risk that gross
margins may not increase as expected, the risk that ViroLogic may not continue
to realize anticipated benefits from its cost-cutting measures, the timing of
pharmaceutical company clinical trials, whether payors will authorize
reimbursement for its products, whether the FDA or any other agency will decide
to regulate ViroLogic's products or services, whether the Company will
encounter problems or delays in automating its processes, whether ViroLogic
successfully introduces new products, whether others introduce competitive
products, whether intellectual property underlying the Company's PhenoSense
technology is adequate, whether licenses to third party technology will be
available, whether ViroLogic is able to build brand loyalty and expand
revenues, and whether ViroLogic will be able to raise sufficient capital when
required. For a discussion of other factors that may cause ViroLogic's actual
events to differ from those projected, please refer to the Company's most
recent annual report on Form 10-K and quarterly reports on Form 10-Q, as well
as other subsequent filings with the Securities and Exchange Commission.
DATASOURCE: ViroLogic, Inc.
CONTACT: Karen Wilson, CFO of ViroLogic, Inc., +1-650-624-4164, or
Web site: http://www.virologic.com/